Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ATF4 | P18848 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074776 | 0.93 | L3MBTL1 (0.51) | SLC6A4SLC6A3MAPTKDM4ELMNA | |
| SCHEMBL6075152 | 0.93 | SLC6A3 (0.50) | SLC6A4SLC6A3MAPTKDM4ELMNA | |
| SCHEMBL6075602 | 0.81 | SLC6A3 (0.56) | SLC6A4SLC6A3L3MBTL1HPGD | |
| SCHEMBL11440981 | 0.78 | MAPT (0.60) | MAPTKDM4ELMNAL3MBTL1ATF4 | |
| SCHEMBL6075323 | 0.78 | SLC6A4 (0.44) | SLC6A4SLC6A3 | |
| SCHEMBL6074941 | 0.78 | SLC6A3 (0.64) | SLC6A4SLC6A3 | |
| SCHEMBL6074974 | 0.78 | SLC6A3 (0.59) | SLC6A4SLC6A3 | |
| SCHEMBL6075236 | 0.76 | SLC6A3 (0.61) | SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL6074896 | 0.75 | SLC6A3 (0.65) | SLC6A4SLC6A3LMNAPOLB | |
| SCHEMBL6076047 | 0.74 | SLC6A4 (0.55) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | SLC6A4 1229/4885SLC6A3 1045/4885MAPT 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.